In agreement, the analysis of the Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Therapeutics Response Portal (CTRP) databases did not indicate differences in the YM155 sensitivity between cell lines in dependence on their TP53 status (wild-type or mutant) (Figure 2). Here, TP53 is linked to cancer.